研发格局：从降糖到代谢综合管理Landscape: From Glucose-Lowering to Comprehensive Metabolic Management Paradigm Shift
过去 20 年糖尿病药物研发经历了三次范式转变：
Over the past 20 years, diabetes drug development has undergone three paradigm shifts:
- 2000s — 单靶点降糖：磺脲、二甲双胍、TZD 等以 HbA1c 为唯一评价
- 2010s — 心肾保护：SGLT2i 与 GLP-1 RA 的 CVOT 颠覆评价标准（EMPA-REG, LEADER）
- 2020s — 代谢综合 + 多受体：tirzepatide / retatrutide 重构肥胖-糖尿病-肝病-心衰治疗矩阵
- 2000s — Single-target glucose-lowering: sulfonylureas, metformin, TZDs etc., evaluated by HbA1c alone
- 2010s — Cardio-renal protection: CVOTs of SGLT2i and GLP-1 RA overturned the evaluation standards (EMPA-REG, LEADER)
- 2020s — Comprehensive metabolic + multi-receptor: tirzepatide / retatrutide reshaped the obesity–diabetes–liver disease–heart failure treatment matrix
当前研发热点：①多受体激动剂（双/三/四/五激动）；②口服肽段/小分子； ③细胞与基因疗法（T1D 治愈）；④免疫调节（疾病修饰）； ⑤器官特异性获益（肝、肾、心、脑）；⑥肠道菌群与精准医学。
Current development hotspots: ① multi-receptor agonists (dual/triple/quadruple/quintuple agonism); ② oral peptides / small molecules; ③ cell and gene therapies (T1D cure); ④ immunomodulation (disease-modifying); ⑤ organ-specific benefits (liver, kidney, heart, brain); ⑥ gut microbiome and precision medicine.
1. 分子靶点全景1. Molecular Target Landscape Molecular Target Landscape
1.1 已验证靶点1.1 Validated Targets Validated
| 靶点 | 家族 | 代表药物 | 核心作用 |
|---|---|---|---|
| Target | Family | Representative drugs | Core action |
| GLP-1R | GPCR (B 类)GPCR (class B) | 司美/利拉/度拉糖肽、orforglipronsemaglutide / liraglutide / dulaglutide, orforglipron | 促胰岛素分泌、抑食欲、胃排空延迟Insulin secretion, appetite suppression, delayed gastric emptying |
| GIPR | GPCR (B 类)GPCR (class B) | tirzepatide (与 GLP-1R 双激动)tirzepatide (dual agonism with GLP-1R) | 促胰岛素、改善脂肪组织功能Insulin secretion, improved adipose tissue function |
| GCGR | GPCR (B 类)GPCR (class B) | retatrutide、survodutide | 增加能量消耗、肝脂肪氧化Increased energy expenditure, hepatic fat oxidation |
| SGLT2 | Sodium-glucose cotransporter | 恩格/达格/卡格列净empagliflozin / dapagliflozin / canagliflozin | 糖尿、轻度利尿、心肾保护Glucosuria, mild diuresis, cardio-renal protection |
| DPP-4 | Serine protease | 西格列汀、利格列汀sitagliptin, linagliptin | 延缓内源 GLP-1/GIP 降解Slows degradation of endogenous GLP-1/GIP |
| 胰岛素受体 IRInsulin receptor (IR) | RTK | 胰岛素与类似物Insulin and analogs | 葡萄糖摄取、代谢调控Glucose uptake, metabolic regulation |
| PPAR-γ | 核受体Nuclear receptor | 吡格列酮pioglitazone | 胰岛素增敏、脂肪重分布Insulin sensitization, fat redistribution |
| CD3 (T1D) | 免疫Immune | teplizumab | T 细胞失能，延缓 T1D 进展T-cell anergy, delays T1D progression |
| α-glucosidase | 消化酶Digestive enzyme | 阿卡波糖、米格列醇acarbose, miglitol | 延缓肠道碳水吸收Slows intestinal carbohydrate absorption |
| K_ATP 通道channel | 胰岛 β 细胞Islet β-cell | 磺脲、格列奈sulfonylureas, glinides | 促胰岛素分泌Insulin secretion |
1.2 新兴 / 前沿靶点1.2 Emerging / Frontier Targets Emerging
| 靶点 | 研发状态 | 战略价值 |
|---|---|---|
| Target | Development status | Strategic value |
| 胰淀素 Amylin / CTRAmylin / CTR | cagrilintide (III 期) + 司美 (CagriSema)cagrilintide (phase III) + semaglutide (CagriSema) | 食欲调控、协同 GLP-1Appetite regulation, synergy with GLP-1 |
| PYY / Y2R | 多个早期项目Several early-stage programs | 肠促胰素增敏、食欲Incretin sensitization, appetite |
| FGF21 / FGFR1c-βKlotho | efruxifermin (II 期 MASH 正面)efruxifermin (positive phase II MASH) | 肝脂肪、纤维化、代谢综合Hepatic fat, fibrosis, metabolic syndrome |
| GDF15 | 动物模型证据；早期临床Animal-model evidence; early clinical | 食欲抑制、能量消耗Appetite suppression, energy expenditure |
| Activin / Myostatin | bimagrumab (II 期与减重药联合)bimagrumab (phase II in combination with weight-loss drugs) | 保留肌肉量，对抗减重药副作用Preserves muscle mass, counters weight-loss drug side effects |
| GHSR (ghrelin antagonism) | 早期Early stage | 抑食欲Appetite suppression |
| Bile acid / TGR5, FXR | 多个 MASH 项目Several MASH programs | 肝脏代谢与胆汁酸轴Hepatic metabolism and bile-acid axis |
| 11β-HSD1 抑制剂11β-HSD1 inhibitors | 历史项目，部分二代正在评估Legacy programs; some second-generation under evaluation | 降低组织内皮质醇Lowers intracellular cortisol |
| 葡萄糖激酶 (GKA)Glucokinase (GKA) | 多扎格列艾汀 (中国获批 2022)dorzagliatin (approved in China 2022) | 独特的 β 细胞和肝脏双重作用Unique dual β-cell and hepatic action |
| FFAR1 / GPR40 | 历史项目失败 (TAK-875 肝毒性)，第二代评估中Legacy program failed (TAK-875 hepatotoxicity); second generation under evaluation | 葡萄糖依赖性促胰岛素Glucose-dependent insulin secretion |
| CD36 (β 细胞cell) | 临床前 / 转化研究Preclinical / translational research | β 细胞脂毒性保护β-cell lipotoxicity protection |
| JAK-STAT / IL-6 / IL-17 (T1D) | 多项 II 期Multiple phase II | 免疫调节、延缓 T1DImmunomodulation, delays T1D |
2. 多受体激动剂战略2. Multi-agonist Strategy Multi-agonist Strategy
"分子的进化"：从单激动剂 → 双激动 → 三激动 → 拮抗 + 激动组合。核心逻辑是 同分子多通路覆盖，提高疗效、改善耐受性、扩展适应症。
"Molecular evolution": from single agonist → dual agonist → triple agonist → antagonist + agonist combinations. The core logic is multi-pathway coverage within a single molecule, improving efficacy, tolerability, and indication expansion.
| 分子 | 受体组合 | 研发方 | 状态 |
|---|---|---|---|
| Molecule | Receptor combination | Developer | Status |
| Tirzepatide | GLP-1 + GIP (双激动)GLP-1 + GIP (dual agonist) | Eli Lilly | 已批 (T2D, 肥胖, OSA)Approved (T2D, obesity, OSA) |
| CagriSema | GLP-1 + Amylin | Novo Nordisk | III 期Phase III |
| Retatrutide | GLP-1 + GIP + GCG (三激动)GLP-1 + GIP + GCG (triple agonist) | Eli Lilly | III 期Phase III |
| Survodutide | GLP-1 + GCG (双激动)GLP-1 + GCG (dual agonist) | BI / Zealand | III 期 (MASH, 肥胖)Phase III (MASH, obesity) |
| Mazdutide | GLP-1 + GCG | Innovent (信达)Innovent | 中国 III 期 / 全球 II 期China phase III / global phase II |
| Efinopegdutide | GLP-1 + GCG | Merck (原 Hanmi)Merck (originally Hanmi) | II 期 MASHPhase II MASH |
| Maridebart cafraglutide (MariTide) | GLP-1 RA + GIPR 拮抗GLP-1 RA + GIPR antagonism | Amgen | II 期 → III 期Phase II → III |
| VK2735 | GLP-1 + GIP 双激动GLP-1 + GIP dual agonist | Viking | II 期 (口服与注射)Phase II (oral and injectable) |
| Ecnoglutide | GLP-1 RA (cAMP 偏向激活)GLP-1 RA (cAMP-biased activation) | Sciwind (来凯)Sciwind | 中国 III 期China phase III |
| 新型五靶点 PDCNovel quintuple-target PDC | GLP-1 + GIP + GCG + PPAR + ? | 学术/早期Academic / early stage | 小鼠模型阳性数据 (C&EN 2026)Positive mouse-model data (C&EN 2026) |
💊 设计要点💊 Design considerations
- 受体偏向性 (biased agonism)：调整 cAMP vs β-arrestin 信号，影响耐受性与降耐
- GIP 双向作用：同一受体的激动与拮抗在不同试验中均显示减重，机制存争议
- 胰高血糖素剂量窗口：过强增加血糖与肝糖输出；需精确配比
- 半衰期工程：脂肪酸链 / Fc / 白蛋白结合 / PEG，决定每周/月给药
- 免疫原性：多受体大肽段需评估抗药抗体风险
- Biased agonism: tuning cAMP vs β-arrestin signaling affects tolerability and tachyphylaxis
- Bidirectional GIP effect: both agonism and antagonism of the same receptor show weight loss across trials; the mechanism remains debated
- Glucagon dose window: excessive activity raises blood glucose and hepatic glucose output; precise ratio tuning required
- Half-life engineering: fatty-acid chains / Fc / albumin binding / PEG determine weekly/monthly dosing
- Immunogenicity: large multi-receptor peptides require assessment of anti-drug antibody risk
来源：Source: Diabetes In Control — GLP-1/GIP Co-Agonist Pipeline 2026 · C&EN — Quintuple Agonist for Obesity/Diabetes
3. 关键临床管线（截至 2026 Q2）3. Key Clinical Pipeline (as of 2026 Q2) Key Pipeline
3.1 T2D / 肥胖 — III 期及以上3.1 T2D / Obesity — Phase III and beyond
- III Retatrutide (Lilly) — TRIUMPH 系列；CV/CKD/MASH outcomes 2026 读出 (CT.gov)
- III CagriSema (Novo) — REDEFINE 系列 (CT.gov)
- III Survodutide (BI) — SYNCHRONIZE (肥胖)、LIVERAGE (MASH) (CT.gov)
- III Insulin Icodec (Novo) — 每周一次基础胰岛素 (部分国家已批) (NEJM ONWARDS)
- III Mazdutide (Innovent) — 中国与全球项目 (CT.gov)
- 2026 Orforglipron (Lilly) — 已获批肥胖；T2D 适应症推进 (GoodRx)
- III Retatrutide (Lilly) — TRIUMPH series; CV/CKD/MASH outcomes readout in 2026 (CT.gov)
- III CagriSema (Novo) — REDEFINE series (CT.gov)
- III Survodutide (BI) — SYNCHRONIZE (obesity), LIVERAGE (MASH) (CT.gov)
- III Insulin Icodec (Novo) — once-weekly basal insulin (approved in some countries) (NEJM ONWARDS)
- III Mazdutide (Innovent) — China and global programs (CT.gov)
- 2026 Orforglipron (Lilly) — approved for obesity; T2D indication advancing (GoodRx)
3.2 T1D 疾病修饰 — II/III 期3.2 T1D Disease Modification — Phase II/III
- III Zimislecel (VX-880) (Vertex) — 干细胞胰岛；2026 注册申请 (Vertex 2025)
- II VX-264 (Vertex) — 封装式胰岛，无需免疫抑制 (Vertex Update)
- II Diamyd (Diamyd Medical) — GAD-alum 免疫疗法 (DIAGNODE-3) (CT.gov)
- II Baricitinib (JAK1/2) — BANDIT 试验 (NEJM 2023)
- II Anti-thymocyte globulin + GCSF — 多项学术研究
- II IBC-VS01 / 多肽疫苗 — 抗原特异性免疫
- I 多个 iPSC 来源 β 细胞项目 (Sernova, Sigilon, Encellin 等)
- III Zimislecel (VX-880) (Vertex) — stem-cell-derived islets; 2026 regulatory filing (Vertex 2025)
- II VX-264 (Vertex) — encapsulated islets, no immunosuppression required (Vertex Update)
- II Diamyd (Diamyd Medical) — GAD-alum immunotherapy (DIAGNODE-3) (CT.gov)
- II Baricitinib (JAK1/2) — BANDIT trial (NEJM 2023)
- II Anti-thymocyte globulin + GCSF — multiple academic studies
- II IBC-VS01 / peptide vaccine — antigen-specific immunity
- I Multiple iPSC-derived β-cell programs (Sernova, Sigilon, Encellin, etc.)
3.3 MASH / MASLD3.3 MASH / MASLD
- 已批Approved Resmetirom (Madrigal) — THR-β (NEJM MAESTRO-NASH)
- 已批Approved Semaglutide (Novo) — GLP-1 RA (NEJM ESSENCE)
- III Survodutide — GLP-1/GCG (CT.gov)
- II→III Efruxifermin (Akero) — FGF21 类似物 (CT.gov)
- II→III Pegozafermin (89bio) — FGF21 类似物
- II Tirzepatide (SYNERGY-NASH)、Retatrutide (NEJM SYNERGY-NASH)
- 已批Approved Resmetirom (Madrigal) — THR-β (NEJM MAESTRO-NASH)
- 已批Approved Semaglutide (Novo) — GLP-1 RA (NEJM ESSENCE)
- III Survodutide — GLP-1/GCG (CT.gov)
- II→III Efruxifermin (Akero) — FGF21 analog (CT.gov)
- II→III Pegozafermin (89bio) — FGF21 analog
- II Tirzepatide (SYNERGY-NASH), Retatrutide (NEJM SYNERGY-NASH)
3.4 糖尿病肾病 (DKD) 与心衰3.4 Diabetic Kidney Disease (DKD) and Heart Failure
- 已批Approved Finerenone (Bayer) — 选择性非甾体 MRA (NEJM FIDELIO-DKD)
- III Aldosterone synthase inhibitors (多家)
- II ASBT 抑制剂、APOL1 抑制剂等
- 已批Approved Finerenone (Bayer) — selective non-steroidal MRA (NEJM FIDELIO-DKD)
- III Aldosterone synthase inhibitors (multiple developers)
- II ASBT inhibitors, APOL1 inhibitors, etc.
实时跟踪：Live tracking:建议通过monitor monthly via
ClinicalTrials.gov ·
FDA Drug Approvals ·
EMA Medicines Database 监控每月动态。 for monthly updates.
4. 未满足的医学需求4. Unmet Medical Needs Unmet Medical Needs
① β 细胞功能恢复
当前药物均不能逆转 T2D 进展。GLP-1 RA 改善而非恢复 β 细胞功能； β 细胞再生（去分化逆转、增殖、转分化）是真正治愈的钥匙。
② T1D 通用治疗
Teplizumab 仅延缓非治愈；Zimislecel 需免疫抑制限制人群。 无需免疫抑制的细胞治疗（如基因编辑 HLA-low / 免疫保护封装）是终极目标。
③ 微血管并发症逆转
DR、DN、DPN 一旦发生多数不可逆。需组织修复 / 神经再生药物 （如抗 AGE-RAGE、抗纤维化、神经营养因子）。
④ 肌肉保留 (Body Composition)
强效减重药 25–40% 的减重为去脂体重，肌少症风险升高。 需肌肉保留剂联合方案（bimagrumab / 活化素 II 受体配体阻断等）。
⑤ 长效与口服
月度甚至季度给药；可口服的高效肽段； 植入或贴片式胰岛素递送。
⑥ 老年与多病共存
老年 T2D 共病多、用药复杂、低血糖风险高； 需简化方案与认知保护导向的治疗。
⑦ 妊娠期安全
大多数新药孕期数据不足。GDM 仍依赖胰岛素； 胎儿安全的口服降糖药研发空间大。
⑧ 可及性与成本
GLP-1 RA 与 SGLT2i 在中低收入国家覆盖率低。 专利到期后仿制药 / 生物类似药策略与定价模式至关重要。
① β-cell function restoration
No current drug reverses T2D progression. GLP-1 RA improves rather than restores β-cell function; β-cell regeneration (reversal of dedifferentiation, proliferation, transdifferentiation) is the key to a true cure.
② Universal T1D therapy
Teplizumab only delays rather than cures; Zimislecel requires immunosuppression, limiting the eligible population. Cell therapy without immunosuppression (e.g., gene-edited HLA-low / immune-protective encapsulation) is the ultimate goal.
③ Reversal of microvascular complications
Once DR, DN, and DPN occur they are mostly irreversible. Tissue-repair / nerve-regeneration drugs are needed (e.g., anti-AGE-RAGE, anti-fibrotic, neurotrophic factors).
④ Muscle preservation (body composition)
For potent weight-loss drugs, 25–40% of the weight lost is lean mass, raising sarcopenia risk. Muscle-preserving combination regimens are needed (bimagrumab / activin type II receptor ligand blockade, etc.).
⑤ Long-acting and oral formulations
Monthly or even quarterly dosing; orally bioavailable potent peptides; implantable or patch-based insulin delivery.
⑥ Elderly and multimorbidity
Elderly T2D patients have multiple comorbidities, complex medication regimens, and high hypoglycemia risk; simplified regimens and cognition-protective therapies are needed.
⑦ Pregnancy safety
Most new drugs have insufficient pregnancy data. GDM still relies on insulin; there is large room to develop fetus-safe oral glucose-lowering drugs.
⑧ Access and cost
GLP-1 RA and SGLT2i have low coverage in low- and middle-income countries. Post-patent generics / biosimilars strategies and pricing models are critical.
5. 生物标志物5. Biomarkers Biomarkers for Drug Development
5.1 诊断与分型5.1 Diagnosis and Classification
- 自身抗体 (T1D)：GAD65, IA-2, ZnT8, IAA — 用于 stage 划分与 DMT 入组
- C-肽：评估内源性胰岛素分泌；T1D 干预 / β 细胞替代试验主要终点
- HbA1c / 果糖胺：降糖药主终点（部分情况已被 TIR 部分替代）
- HOMA-IR / Matsuda index：胰岛素抵抗评估
- HOMA-β / Disposition Index：β 细胞功能评估
- Autoantibodies (T1D): GAD65, IA-2, ZnT8, IAA — used for staging and DMT enrollment
- C-peptide: assesses endogenous insulin secretion; primary endpoint in T1D intervention / β-cell replacement trials
- HbA1c / fructosamine: primary endpoint for glucose-lowering drugs (in some cases partially replaced by TIR)
- HOMA-IR / Matsuda index: insulin resistance assessment
- HOMA-β / Disposition Index: β-cell function assessment
5.2 CGM 衍生 (新一代主终点)5.2 CGM-derived (next-generation primary endpoints)
- TIR (Time in Range)：FDA 接受作为补充临床终点
- GMI、CV、低血糖事件
- 夜间低血糖时间（AID 与基础胰岛素的关键差异点）
- TIR (Time in Range): accepted by FDA as a supportive clinical endpoint
- GMI, CV, hypoglycemic events
- Nocturnal hypoglycemia time (a key differentiator between AID and basal insulin)
5.3 心肾代谢5.3 Cardio-renal-metabolic
- UACR (尿白蛋白/肌酐)、eGFR、eGFR slope：肾试验核心
- NT-proBNP, hs-troponin, KCCQ：心衰试验
- LDL-C, apoB, Lp(a), TG：动脉硬化
- UACR (urine albumin/creatinine), eGFR, eGFR slope: core for renal trials
- NT-proBNP, hs-troponin, KCCQ: heart failure trials
- LDL-C, apoB, Lp(a), TG: atherosclerosis
5.4 肝脏 (MASH)5.4 Liver (MASH)
- 影像：MRI-PDFF (脂肪)、MRE / FibroScan (纤维化)、VCTE LSM
- 血清：ALT/AST, FIB-4, ELF, PRO-C3, ALT 改善 (FDA 接受作为非肝穿主终点)
- 组织学：MASH 缓解 + 不加重纤维化、纤维化降级 (FDA III 期主终点)
- Imaging: MRI-PDFF (fat), MRE / FibroScan (fibrosis), VCTE LSM
- Serum: ALT/AST, FIB-4, ELF, PRO-C3, ALT improvement (accepted by FDA as a non-biopsy primary endpoint)
- Histology: MASH resolution without worsening fibrosis, fibrosis improvement by one stage (FDA phase III primary endpoints)
5.5 探索性 — 微生物组 / 多组学5.5 Exploratory — Microbiome / Multi-omics
- Akkermansia / Faecalibacterium 等菌群作为GLP-1 RA 应答预测因子
- 胆汁酸谱、短链脂肪酸（SCFA）
- 循环 microRNA、外泌体作为 β 细胞应激标志物
- 蛋白组学（SomaScan, Olink）筛选治疗反应标志物
- Bacteria such as Akkermansia / Faecalibacterium as predictors of GLP-1 RA response
- Bile-acid profiles, short-chain fatty acids (SCFA)
- Circulating microRNA and exosomes as β-cell stress markers
- Proteomics (SomaScan, Olink) to screen for treatment-response markers
6. 临床试验设计要点6. Trial Design Considerations Trial Design Considerations
6.1 T2D 降糖药 III 期典型设计6.1 Typical Phase III Design for T2D Glucose-Lowering Drugs
- 主终点：HbA1c 自基线变化（26 周或 52 周）
- 关键次要：HbA1c < 7% 比例、空腹血糖、体重、血压、TIR (CGM 亚组)
- 对照：安慰剂叠加二甲双胍背景；非劣效或优效设计
- 样本量：常 500–1500 例，3 期需多区域注册
- 救援治疗规则、依从性、ESH 检测
- Primary endpoint: change in HbA1c from baseline (26 or 52 weeks)
- Key secondary: proportion achieving HbA1c < 7%, fasting plasma glucose, body weight, blood pressure, TIR (CGM subgroup)
- Control: placebo on a metformin background; non-inferiority or superiority design
- Sample size: usually 500–1500 patients; phase III requires multi-regional registration
- Rescue therapy rules, adherence, ESH monitoring
6.2 心血管 / 肾脏结局试验 (CVOT, KOT)6.2 Cardiovascular / Renal Outcome Trials (CVOT, KOT)
- 主终点：3-point MACE (CV 死亡 + 非致死 MI + 非致死卒中)； 或扩展 4-point (+ 心衰住院)
- 样本量：5000–17000 例；事件驱动；2–5 年随访
- FDA 2008–2020 强制对所有 T2D 新药做 CVOT；2020 起改为风险-收益评估，弹性增加
- Primary endpoint: 3-point MACE (CV death + non-fatal MI + non-fatal stroke); or extended 4-point (+ hospitalization for heart failure)
- Sample size: 5000–17000 patients; event-driven; 2–5 years of follow-up
- From 2008–2020 the FDA mandated a CVOT for all new T2D drugs; since 2020 this shifted to a risk-benefit assessment with greater flexibility
6.3 减重 / 肥胖试验6.3 Weight-loss / Obesity Trials
- 主终点：体重 % 变化、≥ 5% 减重比例
- 持续时间：68 周（FDA 标准）
- 需评估停药反弹、身体成分（DXA 子研究）
- Primary endpoint: percentage change in body weight, proportion achieving ≥ 5% weight loss
- Duration: 68 weeks (FDA standard)
- Must assess weight regain after discontinuation and body composition (DXA substudy)
6.4 T1D 疾病修饰试验6.4 T1D Disease-Modification Trials
- 主终点：2-h MMTT 刺激下 C-肽 AUC；进展至 stage 3 的时间
- 入组：Stage 2 (PROTECT / TN-10 范式) 或新发 (PROTECT)
- 分层：抗体类型、年龄、HLA
- Primary endpoint: C-peptide AUC under 2-h MMTT stimulation; time to progression to stage 3
- Enrollment: Stage 2 (PROTECT / TN-10 paradigm) or newly diagnosed (PROTECT)
- Stratification: antibody type, age, HLA
6.5 细胞与基因疗法6.5 Cell and Gene Therapies
- 主终点：胰岛素独立性、严重低血糖事件归零、C-肽恢复
- 关键挑战：免疫抑制评估、长期植入安全性、致瘤性 (iPSC 来源)
- FDA/EMA 对先进治疗药物 (ATMP) 有专项加速通道
- Primary endpoint: insulin independence, elimination of severe hypoglycemic events, C-peptide restoration
- Key challenges: immunosuppression assessment, long-term graft safety, tumorigenicity (iPSC-derived)
- FDA/EMA provide dedicated accelerated pathways for advanced therapy medicinal products (ATMP)
6.6 MASH 试验6.6 MASH Trials
- 加速批准主终点：(a) MASH 缓解且纤维化不加重 或 (b) 纤维化降级 1 级
- 完全批准：临床终点（肝硬化、肝移植、死亡）— FDA 提出
- 非肝穿替代终点正在快速演进（MRI-PDFF、ELF）
- Accelerated-approval primary endpoint: (a) MASH resolution without worsening fibrosis, or (b) fibrosis improvement by one stage
- Full approval: clinical endpoints (cirrhosis, liver transplant, death) — proposed by FDA
- Non-biopsy surrogate endpoints are evolving rapidly (MRI-PDFF, ELF)
7. 监管路径与关键指导原则7. Regulatory Pathways and Key Guidelines Regulatory
FDA
- Guidance: Evaluating CV Risk in New Antidiabetic Therapies (2008 → 2020 更新)
- Guidance: T2D — Evaluating Safety of New Drugs (2020)
- FDA: Diabetes Drug Development Resources
- Pediatric T2D 扩展性研究 (PREA 强制)
- Noncirrhotic NASH with Liver Fibrosis: Drug Development
- Guidance: Evaluating CV Risk in New Antidiabetic Therapies (2008 → 2020 update)
- Guidance: T2D — Evaluating Safety of New Drugs (2020)
- FDA: Diabetes Drug Development Resources
- Pediatric T2D extension studies (PREA mandated)
- Noncirrhotic NASH with Liver Fibrosis: Drug Development
EMA
中国 NMPAChina NMPA
- CDE：降糖药物临床试验技术指导原则
- 儿童与青少年糖尿病药物开发指导原则（2023）
- 真实世界证据用于糖尿病新药申报的指导（2021）
- CDE: Technical Guideline for Clinical Trials of Glucose-Lowering Drugs
- Guideline for Drug Development in Pediatric and Adolescent Diabetes (2023)
- Guideline on Real-World Evidence for New Diabetes Drug Applications (2021)
ICH
- ICH Efficacy Guidelines：E14 (QT)、E9 (R1) Estimands、E11 (儿童)、M4 (CTD)、Q11 (原料药) 等通用
- ICH Efficacy Guidelines: general guidelines such as E14 (QT), E9 (R1) Estimands, E11 (pediatric), M4 (CTD), Q11 (drug substance)
8. 战略思考 — 给研发团队的清单8. Strategic Considerations — A Checklist for Development Teams Strategic Considerations
- 差异化定位：避免 me-too；新分子应在疗效、安全、给药频率、给药途径、共病覆盖至少一个维度有突破
- 组合而非单兵：多受体激动剂、复方与设备 (CGM + AID + 算法) 是趋势
- "超适应症"思维：从 T2D 出发，规划肥胖、MASH、CKD、HF、神经退行性疾病的平台扩张路线
- 器官保护数据先行：CV/CKD/MASH 数据可显著扩大商业价值（SGLT2i 范式）
- RWD/RWE 与 CGM 数据：真实世界 TIR 与依从性可补充 RCT 不足
- 生物标志物精准分层：预测应答者 (responder) — 提高试验效率、支持差异化定价
- 降低治疗负担：每周/每月制剂、口服剂型、患者报告结局 (PROs) 纳入终点
- 全球同步开发：FDA + EMA + NMPA 同期 III 期，避免上市滞后
- 关注安全长尾：胰腺、甲状腺 C 细胞、胆囊、心率、肝脏、肌肉与骨；长期随访计划
- 支付方对话：欧美付费方对慢病药物的健康经济学要求愈发严格；从早期纳入 HEOR 设计
- Differentiated positioning: avoid me-too; a new molecule should achieve a breakthrough in at least one dimension among efficacy, safety, dosing frequency, route of administration, and comorbidity coverage
- Combinations over single agents: multi-receptor agonists, fixed-dose combinations, and devices (CGM + AID + algorithms) are the trend
- "Beyond-indication" thinking: starting from T2D, plan a platform-expansion route across obesity, MASH, CKD, HF, and neurodegenerative diseases
- Organ-protection data first: CV/CKD/MASH data can substantially expand commercial value (the SGLT2i paradigm)
- RWD/RWE and CGM data: real-world TIR and adherence can complement the limitations of RCTs
- Precise biomarker stratification: predict responders — improving trial efficiency and supporting differentiated pricing
- Reduce treatment burden: weekly/monthly formulations, oral dosage forms, and patient-reported outcomes (PROs) as endpoints
- Global synchronized development: concurrent phase III with FDA + EMA + NMPA to avoid launch delays
- Watch the safety long tail: pancreas, thyroid C-cells, gallbladder, heart rate, liver, muscle, and bone; long-term follow-up plans
- Payer dialogue: US/EU payers have increasingly strict health-economics requirements for chronic-disease drugs; incorporate HEOR design early
📌 快速决策清单（药物研发立项）📌 Quick decision checklist (drug development go/no-go)
- 靶点是否有遗传学/孟德尔随机化证据支持？
- 是否能在 1–2 个临床终点上做出 "≥ 30%" 相对获益？
- 是否有清晰的非劣效以外的差异化叙事？
- 能否设计可成功用于 II 期决策的响应生物标志物？
- 是否预留多适应症的扩张空间？
- 商业化对手是否在 3 年内会推出同类竞品？
- Is the target supported by genetic / Mendelian randomization evidence?
- Can it deliver a "≥ 30%" relative benefit on 1–2 clinical endpoints?
- Is there a clear differentiation narrative beyond non-inferiority?
- Can a response biomarker usable for phase II decision-making be designed?
- Is there reserved room for multi-indication expansion?
- Will commercial competitors launch a same-class product within 3 years?